SMC approval of Cosentyx as first-line

biologic for treatment of nr-axSpA

Thursday 25th March 2021, 19:00–20:30


This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Limited.

UK | March 2021 | 108907

Adverse events should be reported. Reporting forms and information can be found at (UK).

Adverse events should also be reported to Novartis via or online through the pharmacovigilance intake (PVI) tool at

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at

To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners.